Navigation Links
ChanTest Awarded $1 Million Grant for Predictive Assays using Stem Cell-Derived Human Cardiomyocytes
Date:9/17/2012

CLEVELAND, Sept. 17, 2012 /PRNewswire/ -- ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant.  ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes. 

(Logo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO )

"This grant will allow us to optimize our industry-leading cardiomyocyte assays," said ChanTest's Principal Investigator Andrew Bruening-Wright, Ph.D.   "With our collaborators at FDA, DSEC, and Leadscope, Inc., we have improved predictivity models based on currently available ChanTest services.  Our nonclinical models will only get better as we fully integrate cardiomyocyte-based assays." 

These cardiomyocyte assays are critical for improving the predictivity of nonclinical testing and reducing the use of animals as proposed in the NIH roadmap for drug discovery and the FDA's critical path initiative.  The grant will also fund development of automated instrument-based services to increase throughput and drive down costs to meet the needs of ChanTest customers.

Dr. Arthur "Buzz" Brown, founder and CEO of ChanTest and co-PI on the grant, added "ChanTest has assembled an expert team to ensure success of this grant. We'll build on this success to improve drug discovery for other diseases in which ion channels play a critical role."

About ChanTest – The Ion Channel Expert

ChanTest's mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company's library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest's seminal role in the nonclinical cardiac safety field, along with the company's uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

 

CONTACT: Chris Mathes, +1-732-586-1073

 


'/>"/>
SOURCE ChanTest
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ChanTest hires Chris Mathes as Chief Commercial Officer
2. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
3. QBC Diagnostics Awarded GSA Contract
4. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
5. Northwest Bio Awarded $5.5 Million German Government Grant
6. Nonin Medical Awarded Novation Contract for Clinically Proven Pulse Oximeters
7. Elsevier / Gold Standards Kay Morgan Awarded NCPCP Highest Honor
8. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
9. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
10. SurgiCount Medical Awarded Contract From HealthTrust Purchasing Group for the Safety-Sponge® System
11. Sorrento Therapeutics Awarded Third Phase I STTR Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
Breaking Medicine News(10 mins):